Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
McKinsey
Express Scripts
McKesson
Mallinckrodt

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

Vemurafenib - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for vemurafenib and what is the scope of freedom to operate?

Vemurafenib is the generic ingredient in one branded drug marketed by Hoffmann La Roche and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vemurafenib has one hundred and eighty-seven patent family members in forty-five countries.

One supplier is listed for this compound.

Summary for vemurafenib
International Patents:187
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 106
Clinical Trials: 127
Patent Applications: 237
Formulation / Manufacturing:see details
DailyMed Link:vemurafenib at DailyMed
Recent Clinical Trials for vemurafenib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Prospect Creek FoundationPhase 1
OHSU Knight Cancer InstitutePhase 1
Oregon Health and Science UniversityPhase 1

See all vemurafenib clinical trials

Synonyms for vemurafenib
[(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6 -dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl]methanone
1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3- yl)carbonyl)-2,4-difluorophenyl)-
1-PROPANESULFONAMIDE, N-[3-[[5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]CARBONYL]-2,4-DIFLUOROPHENYL]-
1029872-54-5
207SMY3FQT
3og7
4CA-1032
918504-65-1
A25476
AB0031775
AB01273970_03
AB01273970-01
AB1009703
ABP000429
AC-25010
ACN-030372
AK-56796
AKOS007930804
AM81259
AN-1313
ANW-69692
AOB87705
AX8212389
BC626573
BCP25783
BDBM50396483
BRAF(V600E) Kinase Inhibitor RO5185426
BRD-K56343971-001-02-3
BRD-K56343971-001-05-6
C23H18ClF2N3O3S
carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide
CHEBI:63637
CHEMBL1229517
CS-0216
CTK8C3113
D09996
DB08881
DTXSID50238710
EX-A053
EX-A1335
FT-0660388
FT-0675792
FT-0689782
GPXBXXGIAQBQNI-UHFFFAOYSA-N
GTPL5893
HMS3265M03
HMS3265M04
HMS3265N03
HMS3265N04
HMS3654P09
HSDB 8143
HY-12057
J-522975
J-690009
KB-59765
KS-0000002Q
MCULE-7244406627
ME-0096
MolPort-009-200-481
N-(3-((5-(4-Chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4- difluorophenyl)propane-1-sulfonamide
n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-1-propanesulfonamide
N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-B]pyridine
N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)-propane-1-sulfonamide
N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide
N-(3-{(5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl}-2,4- difluorophenyl)propane-1-sulfonamide
N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide
N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-PropanesulfonaMide
N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide
N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-
N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide
NCGC00250399-01
NCGC00250399-05
NSC-761431
NSC761431
PB11741
PLX 4032
PLX-4032
PLX-4032(RG7204)/PLX4032
PLX4032
PLX4032 - Vemurafenib
PLX4032 ,Vemurafenib ,
PLX4032 (Vemurafenib)
PLX4032, RG7204, RO5185426, 1029872-54-5
PLX4032,Vemurafenib, RG7204, RO5185426, Zelboraf
propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
Q-3409
QCR-44
R-7204
RG 7204
RG 7204; Vemurafenib; RO 5185426
RG-7204
RG7204
RL05788
Ro 51-85426
RO 5185426
RO-5185426
RO5185426
s1267
SC-54548
SCHEMBL298931
SR-01000941568
SR-01000941568-1
ST24048327
SW218095-2
SYN1161
TC-158437
TRA0082406
UNII-207SMY3FQT
Vemurafenib (JAN/USAN/INN)
Vemurafenib (PLX4032, RG7204)
Vemurafenib (PLX4032)
Vemurafenib [USAN:INN]
Vemurafenib, RG7204, RO5185426
Vemurafenib;PLX-4032
vemurafenibum
Y0473
Zelboraf
Zelboraf (TN)
ZINC52509366
ZX-AFC000306

US Patents and Regulatory Information for vemurafenib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes   Start Trial   Start Trial   Start Trial
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes   Start Trial   Start Trial   Start Trial
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for vemurafenib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1893612 PA2012010,C1893612 Lithuania   Start Trial PRODUCT NAME: VEMURAFENIBUM; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
1893612 2012/025 Ireland   Start Trial PRODUCT NAME: VEMURAFENIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
1893612 C300534 Netherlands   Start Trial PRODUCT NAME: VEMURAFENIB ALSMEDE FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Dow
Express Scripts
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.